Home » Stocks » IMCR

Immunocore Holdings Limited (IMCR)

Stock Price: $39.26 USD -1.71 (-4.17%)
Updated Jun 21, 2021 12:35 PM EDT - Market open
Market Cap 1.83B
Revenue (ttm) 30.13M
Net Income (ttm) n/a
Shares Out 43.79M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $39.26
Previous Close $40.97
Change ($) -1.71
Change (%) -4.17%
Day's Open 40.84
Day's Range 39.26 - 40.84
Day's Volume 7,079
52-Week Range 30.92 - 61.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

P RESS RELEASE

3 weeks ago - GlobeNewsWire

PRESS RELEASE

1 month ago - GlobeNewsWire

Coinbase's IPO was spectacular. But these stocks with recent IPOs might have better long-term prospects.

Other stocks mentioned: AFRM, RBLX
1 month ago - The Motley Fool

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

2 months ago - GlobeNewsWire

Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary

3 months ago - GlobeNewsWire

The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresectable or met...

4 months ago - Benzinga

About IMCR

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disea... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Bahija Jallal, Ph.D.
Employees
291
Stock Exchange
NASDAQ
Ticker Symbol
IMCR
Full Company Profile

Financial Performance

In 2020, Immunocore's revenue was 30.11 million, an increase of 17.32% compared to the previous year's 25.67 million. Losses were -74.09 million, -28.71% less than in 2019.

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Immunocore is 51.50, which is an increase of 31.18% from the latest price.

Price Target
$51.50
(31.18% upside)